Oncolytics Biotech Inc. (ONC.TO)
Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
2.7600+0.0800 (+2.99%)
At close: 3:59PM EDT
| Previous Close | 2.6800 |
| Open | 2.7400 |
| Bid | 2.7500 x 0 |
| Ask | 2.7800 x 0 |
| Day's Range | 2.6200 - 2.8000 |
| 52 Week Range | 2.3600 - 6.0600 |
| Volume | 65,655 |
| Avg. Volume | 59,722 |
| Market Cap | 151.689M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6290 |
| Earnings Date | Nov. 09, 2021 - Nov. 15, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.74 |
- CNW Group
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.
- Baystreet
Stocks in play: Oncolytics Biotech Inc.
Announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating ...
- CNW Group
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.
© 2021 Verizon Media. All rights reserved.
